Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Seroprevalence of Antibodies to SARS-CoV-2 in Six Sites in the United States, March 23-May 3, 2020

Fiona P. Havers, Carrie Reed, Travis Lim, Joel M. Montgomery, John D. Klena, Aron J. Hall, Alicia M. Fry, Deborah L. Cannon, Cheng-Feng Chiang, Aridth Gibbons, Inna Krapiunaya, Maria Morales-Betoulle, Katherine Roguski, Mohammad Rasheed, Brandi Freeman, Sandra Lester, Lisa Mills, Darin S. Carroll, S. Michele Owen, Jeffrey A. Johnson, Vera Semenova, State Collaborator Group, Jarad Schiffer, View ORCID ProfileNatalie Thornburg, Carina Blackmore, Debra Blog, Angela Dunn, Scott Lindquist, Scott Pritchard, Lynn Sosa, George Turabelidze, John Wiesman, Randall W. Williams
doi: https://doi.org/10.1101/2020.06.25.20140384
Fiona P. Havers
1CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: fhavers@cdc.gov
Carrie Reed
1CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Travis Lim
1CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joel M. Montgomery
1CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John D. Klena
1CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aron J. Hall
1CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alicia M. Fry
1CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deborah L. Cannon
1CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheng-Feng Chiang
1CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aridth Gibbons
1CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Inna Krapiunaya
1CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Morales-Betoulle
1CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katherine Roguski
1CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohammad Rasheed
1CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brandi Freeman
1CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandra Lester
1CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa Mills
1CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Darin S. Carroll
1CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Michele Owen
1CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey A. Johnson
1CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vera Semenova
1CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
2Florida Department of Health, Tallahassee, FL
Jarad Schiffer
1CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natalie Thornburg
1CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Natalie Thornburg
Carina Blackmore
2Florida Department of Health, Tallahassee, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Debra Blog
3New York State Department of Health, Albany, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angela Dunn
4Utah Department of Health, Salt Lake City, UT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott Lindquist
5Washington State Department of Health, Tumwater, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott Pritchard
2Florida Department of Health, Tallahassee, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lynn Sosa
6Connecticut Department of Public Health, Hartford, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George Turabelidze
7Missouri Department of Health and Senior Services, Jefferson City, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Wiesman
5Washington State Department of Health, Tumwater, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Randall W. Williams
7Missouri Department of Health and Senior Services, Jefferson City, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Importance Reported cases of SARS-CoV-2 infection likely underestimate the prevalence of infection in affected communities. Large-scale seroprevalence studies provide better estimates of the proportion of the population previously infected.

Objective To estimate prevalence of SARS-CoV-2 antibodies in convenience samples from several geographic sites in the United States.

Design Serologic testing of convenience samples using residual sera obtained for routine clinical testing by two commercial laboratory companies.

Setting Connecticut (CT), south Florida (FL), Missouri (MO), New York City metro region (NYC), Utah (UT), and Washington State’s (WA) Puget Sound region.

Participants Persons of all ages with serum collected during intervals from March 23 through May 3, 2020.

Exposure SARS-CoV-2 virus infection.

Main outcomes and measures We estimated the presence of antibodies to SARS-CoV-2 spike protein using an ELISA assay. We standardized estimates to the site populations by age and sex. Estimates were adjusted for test performance characteristics (96.0% sensitivity and 99.3% specificity). We estimated the number of infections in each site by extrapolating seroprevalence to site populations. We compared estimated infections to number of reported COVID-19 cases as of last specimen collection date.

Results We tested sera from 11,933 persons. Adjusted estimates of the proportion of persons seroreactive to the SARS-CoV-2 spike protein ranged from 1.13% (95% confidence interval [CI] 0.70-1.94) in WA to 6.93% (95% CI 5.02-8.92) in NYC (collected March 23-April 1). For sites with later collection dates, estimates ranged from 1.85% (95% CI 1.00-3.23, collected April 6-10) for FL to 4.94% (95% CI 3.61-6.52) for CT (April 26-May 3). The estimated number of infections ranged from 6 to 24 times the number of reported cases in each site.

Conclusions and relevance Our seroprevalence estimates suggest that for five of six U.S. sites, from late March to early May 2020, >10 times more SARS-CoV-2 infections occurred than the number of reported cases. Seroprevalence and under-ascertainment varied by site and specimen collection period. Most specimens from each site had no evidence of antibody to SARS-CoV-2. Tracking population seroprevalence serially, in a variety of specific geographic sites, will inform models of transmission dynamics and guide future community-wide public health measures.

Question What proportion of persons in six U.S. sites had detectable antibodies to SARS-CoV-2, March 23-May 3, 2020?

Findings We tested 11,933 residual clinical specimens. We estimate that from 1.1% of persons in the Puget Sound to 6.9% in New York City (collected March 23-April 1) had detectable antibodies. Estimates ranged from 1.9% in south Florida to 4.9% in Connecticut with specimens collected during intervals from April 6-May 3. Six to 24 times more infections were estimated per site with seroprevalence than with case report data.

Meaning For most sites, evidence suggests >10 times more SARS-CoV-2 infections occurred than reported cases. Most persons in each site likely had no detectable SARS-CoV-2 antibodies.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was funded by the Centers for Disease Control and Prevention.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This protocol underwent review by CDC human subjects research officials, who determined that the testing represented non-research activity in the setting of a public health response to the COVID-19 pandemic.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the U.S. Centers for Disease Control and Prevention.

Data Availability

A limited dataset will be made publicly available at a later time.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Back to top
PreviousNext
Posted June 26, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Seroprevalence of Antibodies to SARS-CoV-2 in Six Sites in the United States, March 23-May 3, 2020
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Seroprevalence of Antibodies to SARS-CoV-2 in Six Sites in the United States, March 23-May 3, 2020
Fiona P. Havers, Carrie Reed, Travis Lim, Joel M. Montgomery, John D. Klena, Aron J. Hall, Alicia M. Fry, Deborah L. Cannon, Cheng-Feng Chiang, Aridth Gibbons, Inna Krapiunaya, Maria Morales-Betoulle, Katherine Roguski, Mohammad Rasheed, Brandi Freeman, Sandra Lester, Lisa Mills, Darin S. Carroll, S. Michele Owen, Jeffrey A. Johnson, Vera Semenova, State Collaborator Group, Jarad Schiffer, Natalie Thornburg, Carina Blackmore, Debra Blog, Angela Dunn, Scott Lindquist, Scott Pritchard, Lynn Sosa, George Turabelidze, John Wiesman, Randall W. Williams
medRxiv 2020.06.25.20140384; doi: https://doi.org/10.1101/2020.06.25.20140384
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Seroprevalence of Antibodies to SARS-CoV-2 in Six Sites in the United States, March 23-May 3, 2020
Fiona P. Havers, Carrie Reed, Travis Lim, Joel M. Montgomery, John D. Klena, Aron J. Hall, Alicia M. Fry, Deborah L. Cannon, Cheng-Feng Chiang, Aridth Gibbons, Inna Krapiunaya, Maria Morales-Betoulle, Katherine Roguski, Mohammad Rasheed, Brandi Freeman, Sandra Lester, Lisa Mills, Darin S. Carroll, S. Michele Owen, Jeffrey A. Johnson, Vera Semenova, State Collaborator Group, Jarad Schiffer, Natalie Thornburg, Carina Blackmore, Debra Blog, Angela Dunn, Scott Lindquist, Scott Pritchard, Lynn Sosa, George Turabelidze, John Wiesman, Randall W. Williams
medRxiv 2020.06.25.20140384; doi: https://doi.org/10.1101/2020.06.25.20140384

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (51)
  • Cardiovascular Medicine (455)
  • Dentistry and Oral Medicine (83)
  • Dermatology (55)
  • Emergency Medicine (159)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (191)
  • Epidemiology (5297)
  • Forensic Medicine (3)
  • Gastroenterology (198)
  • Genetic and Genomic Medicine (760)
  • Geriatric Medicine (80)
  • Health Economics (214)
  • Health Informatics (702)
  • Health Policy (363)
  • Health Systems and Quality Improvement (224)
  • Hematology (100)
  • HIV/AIDS (165)
  • Infectious Diseases (except HIV/AIDS) (5938)
  • Intensive Care and Critical Care Medicine (368)
  • Medical Education (105)
  • Medical Ethics (25)
  • Nephrology (83)
  • Neurology (772)
  • Nursing (43)
  • Nutrition (135)
  • Obstetrics and Gynecology (146)
  • Occupational and Environmental Health (234)
  • Oncology (481)
  • Ophthalmology (153)
  • Orthopedics (39)
  • Otolaryngology (97)
  • Pain Medicine (39)
  • Palliative Medicine (20)
  • Pathology (141)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (138)
  • Primary Care Research (99)
  • Psychiatry and Clinical Psychology (865)
  • Public and Global Health (2035)
  • Radiology and Imaging (354)
  • Rehabilitation Medicine and Physical Therapy (159)
  • Respiratory Medicine (287)
  • Rheumatology (94)
  • Sexual and Reproductive Health (74)
  • Sports Medicine (77)
  • Surgery (110)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)